Literature DB >> 16009677

5-HT3 receptor antagonists ameliorate fatigue: so much potential, so little knowledge!

N M Barnes1.   

Abstract

There is growing evidence that 5-HT3 receptor blockade will benefit patients with fatigue. Further research is needed to determine the mechanism underlying this widespread clinically important symptom and therapies may be derived from targeting the 5-HT system.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16009677      PMCID： PMC1774874          DOI： 10.1136/gut.2004.063545

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  24 in total

1.  The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit.

Authors:  A E Dubin; R Huvar; M R D'Andrea; J Pyati; J Y Zhu; K C Joy; S J Wilson; J E Galindo; C A Glass; L Luo; M R Jackson; T W Lovenberg; M G Erlander
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

Review 2.  A review of central 5-HT receptors and their function.

Authors:  N M Barnes; T Sharp
Journal:  Neuropharmacology       Date:  1999-08       Impact factor: 5.250

3.  Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy.

Authors:  E A Jones
Journal:  Lancet       Date:  1999-07-31       Impact factor: 79.321

Review 4.  The medical benefit of 5-HT research.

Authors:  Brian J Jones; Thomas P Blackburn
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

5.  Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors.

Authors:  C A Brady; I M Stanford; I Ali; L Lin; J M Williams; A E Dubin; A G Hope; N M Barnes
Journal:  Neuropharmacology       Date:  2001-08       Impact factor: 5.250

6.  Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results.

Authors:  M Späth; D Welzel; L Färber
Journal:  Scand J Rheumatol Suppl       Date:  2000

7.  Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635.

Authors:  Anthony J Cleare; Cristina Messa; Eugenii A Rabiner; Paul M Grasby
Journal:  Biol Psychiatry       Date:  2005-02-01       Impact factor: 13.382

8.  Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study.

Authors:  T Piche; G Vanbiervliet; F Cherikh; Z Antoun; P M Huet; E Gelsi; J-F Demarquay; F-X Caroli-Bosc; S Benzaken; M-C Rigault; C Renou; P Rampal; A Tran
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

9.  Reduction of serotonin transporters of patients with chronic fatigue syndrome.

Authors:  Shigeyuki Yamamoto; Yasuomi Ouchi; Hirotaka Onoe; Etsuji Yoshikawa; Hideo Tsukada; Hidetoshi Takahashi; Masao Iwase; Kouzi Yamaguti; Hirohiko Kuratsune; Yasuyoshi Watanabe
Journal:  Neuroreport       Date:  2004-12-03       Impact factor: 1.837

10.  The 5-HT3B subunit is a major determinant of serotonin-receptor function.

Authors:  P A Davies; M Pistis; M C Hanna; J A Peters; J J Lambert; T G Hales; E F Kirkness
Journal:  Nature       Date:  1999-01-28       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.